Business Context and Reporting Period
Company: PMGC Holdings Inc. (formerly Elevai Labs Inc.)
Filing Type: Form 10-K (Annual Report)
Period: Fiscal Year Ended December 31, 2024
Reporting Status: Non-accelerated filer, Smaller reporting company, Emerging growth company.
Business Model: PMGC has transitioned from a skincare developer to a diversified biotechnology holding company. Following the divestiture of its Elevai Skincare business (closed January 16, 2025), the Company now operates three wholly owned subsidiaries: Northstrive Biosciences Inc. (biopharmaceutical development), PMGC Research Inc. (medical scientific R&D), and PMGC Capital LLC (multi-strategy investment firm).
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue (Continuing Ops) | $0 | $0 |
| Revenue (Discontinued Ops) | $2,467,298 | $1,712,595 |
| Total Net Loss | $(6,245,737) | $(4,301,517) |
| Net Loss (Continuing Ops) | $(4,016,714) | $(1,656,739) |
| Net Loss (Discontinued Ops) | $(2,229,023) | $(2,644,778) |
| Total Operating Expenses (Continuing) | $3,663,566 | $1,140,958 |
| Cash and Cash Equivalents (Year End) | $3,984,453 | $3,326,851 |
| Working Capital | $4,251,867 | $3,622,091 |
| Accumulated Deficit | $(13,269,627) | $(7,023,890) |
Note: The filing does not provide specific gross margin percentages for continuing operations as there is no revenue. Discontinued operations (skincare) generated revenue but resulted in a net loss.
Material Changes vs. Prior Period
- Strategic Pivot: The Company completed the divestiture of its Elevai Skincare business in January 2025. Consequently, 2024 results include significant discontinued operations, while the core business is now focused on biotechnology assets and investments.
- Expense Surge: Total operating expenses for continuing operations increased by approximately 219% (from $1.14M to $3.66M). This was driven by:
- Consulting Fees: Increased by $1.09M to $1.37M, largely due to increased compensation for key management and accrued bonuses.
- Professional Fees: Increased by $430k to $563k due to NASDAQ listing compliance costs.
- Office & Admin: Increased by $745k to $1.09M, including full-year D&O insurance and director fees.
- Intangible Assets: The Company acquired two significant intangible assets in 2024: License #1 (stem cell technology, terminated Feb 2025) and License #2 (EL-22/EL-32 probiotic technology for obesity/muscle preservation), totaling $2.88M in cost.
- Financing Activity: The Company raised approximately $6.99M through the issuance of common stock and warrants and $914k via Notes in 2024, compared to $1.46M in stock and $5.24M in IPO proceeds in 2023.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Primary Focus: Advancing the clinical development of Northstrive Biosciences' lead asset, EL-22 (an engineered probiotic for muscle preservation during weight loss), with a planned Investigational New Drug (IND) submission in 2025.
- Investment Strategy: PMGC Capital LLC will focus on direct investments, strategic lending, and acquiring undervalued assets.
- Liquidity: Management expects liquidity to improve following the sale of the loss-making skincare business. However, the Company requires additional equity financing to fund operations and R&D.
Risks and Contingencies
- Going Concern: The auditors have issued a "Going Concern" opinion. The Company has incurred recurring losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern without additional financing.
- Regulatory Risk: Success depends on FDA clearance of the IND for EL-22. Regulatory bodies may require additional preclinical bridge studies.
- Intellectual Property: The Company relies on licensed technology (MOA Life Plus Co., Ltd.). Termination of these licenses would halt development.
- Internal Controls: Management identified a material weakness in internal control over financial reporting regarding accounting policies and standardized reconciliation schedules.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $3.98M cash balance against the projected burn rate for 2025, given the lack of revenue from continuing operations.
- EL-22 Clinical Timeline: Confirm the status of the planned 2025 IND submission and any requirements for additional preclinical data.
- License #1 Termination: Review the financial impact of the February 2025 termination of the INmune Bio license and the release of the $950k obligation.
- Related Party Transactions: Scrutinize the significant consulting fees paid to entities controlled by the CEO (GB Capital Ltd.) and Chairman (Northstrive Companies Inc.), which totaled over $750k in 2024.
- Stock Dilution: Assess the impact of recent and planned equity issuances, including the March 2025 registered direct offering and the issuance of Series B Preferred Stock to related parties.